Wedbush reiterated their neutral rating on shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) in a research note issued to investors on Monday, Marketbeat reports. Wedbush also issued estimates for Global Blood Therapeutics' Q3 2022 earnings at ($1.35) EPS, Q4 2022 earnings at ($1.31) EPS, FY2022 earnings at ($5.17) EPS, Q1 2023 earnings at ($1.28) EPS, Q2 2023 earnings at ($1.31) EPS, Q3 2023 earnings at ($1.36) EPS, Q4 2023 earnings at ($0.67) EPS, FY2023 earnings at ($4.62) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at $3.41 EPS.

A number of other research firms have also commented on GBT. JPMorgan Chase & Co. reduced their target price on Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating for the company in a report on Tuesday, June 28th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the stock from $40.00 to $72.00 in a report on Monday. StockNews.com raised Global Blood Therapeutics from a sell rating to a hold rating in a report on Thursday, May 5th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the stock from $40.00 to $72.00 in a report on Monday. Finally, William Blair lowered Global Blood Therapeutics from an outperform rating to a market perform rating in a report on Monday. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $65.04.

Global Blood Therapeutics Trading Down 0.4 %

GBT opened at $66.57 on Monday. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02. The company has a quick ratio of 7.74, a current ratio of 6.88 and a debt-to-equity ratio of 4.92. The stock has a market cap of $4.33 billion, a PE ratio of -13.29 and a beta of 0.83. The business has a 50 day moving average of $34.55 and a 200-day moving average of $31.84.

Insider Transactions at Global Blood Therapeutics

In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the sale, the director now directly owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.90% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in Global Blood Therapeutics during the first quarter worth $17,322,000. Deep Track Capital LP purchased a new stake in Global Blood Therapeutics during the fourth quarter worth $58,540,000. Goldman Sachs Group Inc. lifted its holdings in Global Blood Therapeutics by 48.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,833,720 shares of the company's stock worth $63,520,000 after buying an additional 595,983 shares during the period. Fairmount Funds Management LLC lifted its holdings in Global Blood Therapeutics by 59.1% during the first quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock worth $40,955,000 after buying an additional 439,307 shares during the period. Finally, Quinn Opportunity Partners LLC purchased a new stake in shares of Global Blood Therapeutics during the 1st quarter valued at $1,249,000.

Global Blood Therapeutics Company Profile

(Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Read More

• Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?
• Find and Profitably Trade Stocks at 52-Week Lows
• Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
• Solar Stocks Shine Brightly After Passage Of Clean Energy Bill

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.